Financial Performance - The company's revenue for Q1 2023 was CNY 240,206,327.57, representing an increase of 82.92% compared to CNY 131,319,672.55 in the same period last year[4]. - The net loss attributable to shareholders for Q1 2023 was CNY -17,309,522.74, a decrease of 101.66% from CNY -8,583,730.95 in Q1 2022[4]. - Net profit for Q1 2023 is -17,309,522.74 RMB, a decrease of 101.66% compared to Q1 2022[14]. - The basic and diluted earnings per share were both -¥0.16, worsening from -¥0.09 in the previous period[28]. - Total operating revenue for the current period reached ¥240,206,327.57, a significant increase from ¥131,319,672.55 in the previous period, representing an increase of approximately 83%[26]. - The net loss for the current period was ¥17,309,522.74, compared to a net loss of ¥8,583,730.95 in the previous period, reflecting an increase in losses of approximately 102%[28]. Cash Flow - The net cash flow from operating activities was CNY -205,749,592.42, a decline of 6.47% compared to CNY -193,250,545.06 in the previous year[4]. - Cash flow from operating activities showed a net outflow of ¥205,749,592.42, compared to a net outflow of ¥193,250,545.06 in the previous period[30]. - Investment activities generated a net cash flow of 404,394,431.90 RMB, a 178.15% increase from the previous year[15]. - Cash flow from investing activities generated a net inflow of ¥404,394,431.90, contrasting with a net outflow of ¥517,453,534.57 in the previous period[30]. - Financing activities resulted in a net cash flow of 97,149,635.24 RMB, down 88.25% from the previous year[15]. - Cash flow from financing activities resulted in a net inflow of ¥97,149,635.24, down from ¥826,578,481.17 in the previous period[32]. - The ending cash and cash equivalents balance was ¥429,125,286.77, an increase from ¥305,091,543.28 in the previous period[32]. - The company's cash and cash equivalents increased by 120.10% to CNY 555,284,119.25, primarily due to the maturity of idle raised funds[11]. Assets and Liabilities - As of the end of Q1 2023, the company had a total asset value of CNY 2,319,324,309.61, a decrease of 2.14% from CNY 2,369,993,275.66 at the end of the previous year[4]. - The total current assets as of March 31, 2023, amounted to CNY 2,086,325,371.35, a decrease from CNY 2,133,466,006.70 at the beginning of the year[21]. - Total liabilities decreased to CNY 670,385,913.93 from CNY 717,195,126.15, a reduction of about 6.5%[23]. - The total assets as of March 31, 2023, were CNY 2,319,324,309.61, down from CNY 2,369,993,275.66 at the beginning of the year[23]. - The company's equity attributable to shareholders decreased to CNY 1,648,938,395.68 from CNY 1,652,798,149.51, a decline of approximately 0.2%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,691[14]. - Major shareholder, Tan Pingtao, holds 44.23% of the shares, totaling 46,708,990 shares[14]. - Sun Life Insurance Company holds 6.50% of the shares, totaling 6,864,046 shares[14]. - The company has a total of 10 major shareholders, with varying percentages of ownership[16]. - The company has a total of 80,558,504 shares under lock-up agreements, with 25,312,294 shares released during the period[19]. Research and Development - Research and development expenses increased by 129.32% to CNY 23,300,468.90 compared to CNY 10,160,474.31 in Q1 2022[12]. - The company is focusing on R&D investments, which have increased during the reporting period[14]. - Research and development expenses for the current period were ¥23,300,468.90, significantly higher than ¥10,160,474.31 in the previous period, marking an increase of approximately 129%[26]. Operational Expenses - Operating expenses increased significantly, contributing to the net loss[14]. - Sales expenses rose by 40.04% to CNY 33,931,560.78, driven by an increase in sales personnel and marketing costs[12]. - Total operating costs amounted to ¥267,516,174.95, up from ¥146,259,169.33, indicating a rise of about 83%[26]. Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[22]. - The company reported a significant increase in cash flow, which will support future investments and operational needs[21].
华康医疗(301235) - 2023 Q1 - 季度财报